Medicine guide

Betmiga

·

  • Prescription status not stated
  • Urinary and reproductive system, hormones
Active substance
Mirabegron
Made by
Astellas Pharma Europe B.V.

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

  • Overactive bladder in adults  Betmiga prolonged-release tablets are indicated for symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.  Neurogenic detrusor overactivity in the paediatric population  Betmiga prolonged release tablets are indicated for treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years.

From the official label · 2026-09-30 · European Medicines Agency

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

BulgariaNo exact match for this strength and form

SpainNo exact match for this strength and form

CanadaNo exact match for this strength and form

NetherlandsNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byAstellas Pharma Europe B.V.
Active substanceMirabegron
Used inUrinary and reproductive system, hormones
ClassificationG04BD12 · Urinary and reproductive system, hormones
Authorised on2012-12-20
Last updated by the regulator2025-08-27
EMA product numberEMEA/H/C/002388

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).